

# Zhixiang Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5441687/publications.pdf>

Version: 2024-02-01

91  
papers

4,718  
citations

147801

31  
h-index

102487

66  
g-index

94  
all docs

94  
docs citations

94  
times ranked

7579  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	2
2	A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. <i>Cancer</i> , 2022, , .	4.1	5
3	Regulation of the nuclear speckle localization and function of Rac1. <i>FASEB Journal</i> , 2021, 35, e21235.	0.5	2
4	Drug Resistance and Novel Therapies in Cancers in 2019. <i>Cancers</i> , 2021, 13, 924.	3.7	2
5	Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2021, 19, 117.	4.4	7
6	Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 554503.	2.8	8
7	Metagenomic next-generation sequencing for identifying pathogens in central nervous system complications after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1978-1983.	2.4	14
8	Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with <scp>MDSâ€EB</scp>â€1 or <scp>MDSâ€EB</scp>â€2. <i>International Journal of Cancer</i> , 2021, 149, 1109-1120.	5.1	6
9	Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. <i>Cancers</i> , 2021, 13, 3540.	3.7	50
10	Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. <i>Life</i> , 2021, 11, 868.	2.4	6
11	Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling. <i>Cells</i> , 2021, 10, 3327.	4.1	76
12	IKZF1 deletions Coupled with CD20 Expression Represents a Novel High-Risk Subtype in Adult B-Cell Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 4474-4474.	1.4	0
13	Differential Subcellular Distribution and Translocation of Seven 14-3-3 Isoforms in Response to EGF and During the Cell Cycle. <i>International Journal of Molecular Sciences</i> , 2020, 21, 318.	4.1	18
14	Angioregulatory microRNAs in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 71.	3.7	31
15	Ultrasound-assisted magnetic nanoparticle-based gene delivery. <i>PLoS ONE</i> , 2020, 15, e0239633.	2.5	2
16	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1201-1212.	10.7	209
17	Drug Resistance and Novel Therapies in Cancers. <i>Cancers</i> , 2020, 12, 2929.	3.7	2
18	Early T-Cell Precursor Leukemia Has a Higher Risk of Induction-Related Infection among T-Cell Acute Lymphoblastic Leukemia in Adult. <i>Mediators of Inflammation</i> , 2020, 2020, 1-10.	3.0	8

#	ARTICLE	IF	CITATIONS
19	Prophylactic Donor Lymphocyte Infusion Based on Two Different Time for Preventing Relapse in Advanced Acute Leukemia Undergoing Allo-HSCT: Comparison of Two Independent Prospective Cohorts. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
20	Combination of Homoharringtonine with Venetoclax and Azacitidine Exerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-27.	1.4	4
21	MicroRNA-144 targets APP to regulate AML1/ETO+ leukemia cell migration via the ERK/Myc/MMP2 pathway. <i>Oncology Letters</i> , 2019, 18, 2034-2042.	1.8	9
22	Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7477-7488.	2.0	12
23	Rac1 S71 Mediates the Interaction between Rac1 and 14-3-3 Proteins. <i>Cells</i> , 2019, 8, 1006.	4.1	12
24	The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation. <i>Cancers</i> , 2019, 11, 375.	3.7	18
25	The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 5659-5659.	1.4	0
26	Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia. <i>Oncology Letters</i> , 2018, 15, 917-925.	1.8	7
27	Polyethylenimine-coated iron oxide magnetic nanoparticles for high efficient gene delivery. <i>Applied Nanoscience (Switzerland)</i> , 2018, 8, 811-821.	3.1	18
28	Regulation of EGFR Endocytosis by CBL During Mitosis. <i>Cells</i> , 2018, 7, 257.	4.1	16
29	Post-Translational Modification and Subcellular Distribution of Rac1: An Update. <i>Cells</i> , 2018, 7, 263.	4.1	47
30	Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. <i>Cancers</i> , 2018, 10, 342.	3.7	109
31	The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. <i>BMC Cancer</i> , 2018, 18, 238.	2.6	33
32	Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. <i>Cancers</i> , 2018, 10, 274.	3.7	83
33	An In Vitro Kinase Assay to Assess Rac1 Phosphorylation by ERK. <i>Methods in Molecular Biology</i> , 2018, 1821, 131-140.	0.9	1
34	A potential anticancer ability of 1,2-di(quinazolin-4-yl)diselane against gastric cancer cells through ROS signaling pathway. <i>Medicinal Chemistry Research</i> , 2017, 26, 841-848.	2.4	4
35	Two-Pulse Endosomal Stimulation of Receptor Tyrosine Kinases Induces Cell Proliferation. <i>Methods in Molecular Biology</i> , 2017, 1652, 127-133.	0.9	1
36	ErbB Receptors and Cancer. <i>Methods in Molecular Biology</i> , 2017, 1652, 3-35.	0.9	283

#	ARTICLE	IF	CITATIONS
37	Study of EGFR Signaling/Endocytosis by Site-Directed Mutagenesis. <i>Methods in Molecular Biology</i> , 2017, 1652, 135-143.	0.9	0
38	Cell Cycle Synchronization of HeLa Cells to Assay EGFR Pathway Activation. <i>Methods in Molecular Biology</i> , 2017, 1652, 167-181.	0.9	12
39	Application of Immunofluorescence Staining to Study ErbB Family of Receptor Tyrosine Kinases. <i>Methods in Molecular Biology</i> , 2017, 1652, 109-116.	0.9	3
40	Activation of Endosome-Associated Inert EGF Receptor Following Internalization. <i>Methods in Molecular Biology</i> , 2017, 1652, 117-126.	0.9	1
41	Dimerization Assessment of Epithelial Growth Factor Family of Receptor Tyrosine Kinases by Using Cross-Linking Reagent. <i>Methods in Molecular Biology</i> , 2017, 1652, 101-108.	0.9	3
42	Analysis of Epidermal Growth Factor Receptor-Induced Cell Motility by Wound Healing Assay. <i>Methods in Molecular Biology</i> , 2017, 1652, 159-163.	0.9	6
43	Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	2
44	Interaction between Rho GTPases and 14-3-3 Proteins. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2148.	4.1	29
45	HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance. <i>Cancers</i> , 2017, 9, 40.	3.7	60
46	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. <i>Cancers</i> , 2017, 9, 52.	3.7	1,153
47	MicroRNA-31 Function as a Suppressor Was Regulated by Epigenetic Mechanisms in Gastric Cancer. <i>BioMed Research International</i> , 2017, 2017, 1-11.	1.9	20
48	Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents. <i>PLoS ONE</i> , 2017, 12, e0182400.	2.5	19
49	Gli-1/PI3K/AKT/NF- $\kappa$ B pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells. <i>Oncotarget</i> , 2016, 7, 33004-33015.	1.8	59
50	Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research. <i>International Journal of Molecular Sciences</i> , 2016, 17, 95.	4.1	99
51	Non-Ligand-Induced Dimerization is Sufficient to Initiate the Signalling and Endocytosis of EGF Receptor. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1200.	4.1	9
52	Phosphorylation and Activation of RhoA by ERK in Response to Epidermal Growth Factor Stimulation. <i>PLoS ONE</i> , 2016, 11, e0147103.	2.5	40
53	Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway. <i>Oncology Reports</i> , 2016, 36, 1626-1632.	2.6	12
54	Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 11409-11420.	1.8	10

#	ARTICLE	IF	CITATIONS
55	The chloride intracellular channel 5A stimulates podocyte Rac1, protecting against hypertension-induced glomerular injury. <i>Kidney International</i> , 2016, 89, 833-847.	5.2	18
56	The Relationship between Clinical Feature, Complex Immunophenotype, Chromosome Karyotype, and Outcome of Patients with Acute Myeloid Leukemia in China. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	120
57	Palliative chemotherapy followed by methylation inhibitor in high-risk acute myeloid leukemia: An in vitro and clinical study. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1139-1144.	1.0	2
58	Personalized medicine for HER2-positive breast cancer. <i>Breast Cancer Management</i> , 2015, 4, 237-240.	0.2	2
59	EGF stimulates the activation of EGF receptors and the selective activation of major signaling pathways during mitosis. <i>Cellular Signalling</i> , 2015, 27, 638-651.	3.6	38
60	Dimerization drives EGF receptor endocytosis through two sets of compatible endocytic codes. <i>Journal of Cell Science</i> , 2015, 128, 935-50.	2.0	21
61	The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. <i>Oncotarget</i> , 2015, 6, 33612-33622.	1.8	26
62	The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients. <i>Blood</i> , 2015, 126, 4932-4932.	1.4	0
63	APP Gene Involves in the Regulation of Cell Apoptosis in AML1-ETO-Positive Leukemia Via SCF/c-Kit Signaling Pathway. <i>Blood</i> , 2015, 126, 3647-3647.	1.4	0
64	Identification of Novel Molecular Markers for Prognosis Estimation of Acute Myeloid Leukemia: Over-Expression of PDCD7, FIS1 and Ang2 May Indicate Poor Prognosis in Pretreatment Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e84150.	2.5	33
65	Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. <i>BMC Cancer</i> , 2014, 14, 37.	2.6	58
66	Hh/IGF-1R/PI3K/Akt/MRP1 Pathway Induce Refractory Acute Myeloid Leukemia and Its Targeting Therapy. <i>Blood</i> , 2014, 124, 3612-3612.	1.4	7
67	The EGF receptor is activated during mitosis and its cell signaling is mediated differently than in interphase (802.13). <i>FASEB Journal</i> , 2014, 28, 802.13.	0.5	0
68	Decitabine Act As Demethylation Modulators in Acute Myeloid Leukemia for Reversal of Drug Resistance. <i>Blood</i> , 2014, 124, 5218-5218.	1.4	0
69	APP Gene Is Correlated with C-KIT Mutations and Indicates Poor Disease Outcome in AML1-ETO-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 942-942.	1.4	0
70	Phosphorylation of Rac1 T108 by Extracellular Signal-Regulated Kinase in Response to Epidermal Growth Factor: a Novel Mechanism To Regulate Rac1 Function. <i>Molecular and Cellular Biology</i> , 2013, 33, 4538-4551.	2.3	46
71	Molecular Mechanism Of Regulation Of Extramedullary Infiltration In AML1/ETO Positive Acute Myeloid Leukemia By APP/ERK/MMP-2. <i>Blood</i> , 2013, 122, 3769-3769.	1.4	0
72	Differential Regulation of Transcription Factors by Location-Specific EGF Receptor Signaling via a Spatio-Temporal Interplay of ERK Activation. <i>PLoS ONE</i> , 2012, 7, e41354.	2.5	32

#	ARTICLE	IF	CITATIONS
73	Regulation of EGF-stimulated EGF Receptor Endocytosis During M Phase. <i>Traffic</i> , 2011, 12, 201-217.	2.7	27
74	Dimerization drives PDGF receptor endocytosis through a C-terminal hydrophobic motif shared by EGF receptor. <i>Experimental Cell Research</i> , 2010, 316, 2237-2250.	2.6	20
75	PLC- $\beta$ 1 and Rac1 Coregulate EGF-Induced Cytoskeleton Remodeling and Cell Migration. <i>Molecular Endocrinology</i> , 2009, 23, 901-913.	3.7	68
76	A Tale of Two Cbls: Interplay of c-Cbl and Cbl-b in Epidermal Growth Factor Receptor Downregulation. <i>Molecular and Cellular Biology</i> , 2008, 28, 3020-3037.	2.3	78
77	Identification of EGF receptor C-terminal sequences 1005-1017 and di-leucine motif 1010LL1011 as essential in EGF receptor endocytosis. <i>Experimental Cell Research</i> , 2007, 313, 3349-3363.	2.6	42
78	Akt Binds to and Phosphorylates Phospholipase C- $\beta$ 1 in Response to Epidermal Growth Factor. <i>Molecular Biology of the Cell</i> , 2006, 17, 2267-2277.	2.1	58
79	Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. <i>EMBO Reports</i> , 2005, 6, 942-948.	4.5	129
80	Platelet-derived Growth Factor Receptor-mediated Signal Transduction from Endosomes. <i>Journal of Biological Chemistry</i> , 2004, 279, 8038-8046.	3.4	123
81	Stimulation of Cell Proliferation by Endosomal Epidermal Growth Factor Receptor As Revealed through Two Distinct Phases of Signaling. <i>Molecular and Cellular Biology</i> , 2003, 23, 5803-5815.	2.3	93
82	Internalization of Inactive EGF Receptor into Endosomes and the Subsequent Activation of Endosome-Associated EGF Receptors. <i>Science Signaling</i> , 2002, 2002, pl17-pl17.	3.6	27
83	Endosomal Signaling of Epidermal Growth Factor Receptor Stimulates Signal Transduction Pathways Leading to Cell Survival. <i>Molecular and Cellular Biology</i> , 2002, 22, 7279-7290.	2.3	253
84	Phospholipase C- $\beta$ 1: A Phospholipase and Guanine Nucleotide Exchange Factor. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2002, 2, 352-355.	3.4	12
85	Regulation of epidermal growth factor receptor endocytosis by wortmannin through activation of Rab5 rather than inhibition of phosphatidylinositol 3-kinase. <i>EMBO Reports</i> , 2001, 2, 842-849.	4.5	46
86	Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. <i>Molecular and Cellular Biology</i> , 2001, 21, 1540-1551.	2.3	147
87	Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3. <i>Biochemical and Biophysical Research Communications</i> , 2000, 277, 757-763.	2.1	131
88	Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation. <i>Molecular Biology of the Cell</i> , 1999, 10, 1621-1636.	2.1	170
89	The Mode of Action of Taxol: Apoptosis at Low Concentration and Necrosis at High Concentration. <i>Biochemical and Biophysical Research Communications</i> , 1999, 263, 398-404.	2.1	144
90	Requirement for Phospholipase C- $\beta$ 1 Enzymatic Activity in Growth Factor-Induced Mitogenesis. <i>Molecular and Cellular Biology</i> , 1998, 18, 590-597.	2.3	98

#	ARTICLE	IF	CITATIONS
91	Mutual Regulation of Receptor-Mediated Cell Signalling and Endocytosis: EGF Receptor System as an Example. , 0, , .		3